Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 1Recurrence 1Prostatic Neoplasms 1

Interventions

pembrolizumab 1265Specimen Handling 926Magnetic Resonance Spectroscopy 830Carboplatin 823Cyclophosphamide 800Cisplatin 723Nivolumab 669Paclitaxel 627Radiotherapy 611Gemcitabine 573Biopsy 557Bevacizumab 478Dexamethasone 438fludarabine 407Docetaxel 380venetoclax 368Oxaliplatin 364Capecitabine 358Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 330Drug Therapy 326Doxorubicin 316Radiosurgery 315Standard of Care 309Blood Specimen Collection 308Pemetrexed 305Ipilimumab 299Radiation 286

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Dutasteride × 1 year × Clear all
NCT07420517 2026-03-30

DutaBCa-1

CHU de Quebec-Universite Laval

Phase 2 Recruiting
95 enrolled
Genitourinary

Urinary Bladder Neoplasms, Recurrence

NCT01653925 2025-11-24

Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression

CHU de Quebec-Universite Laval

Phase NA Active not recruiting
120 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡